Roth Capital raised the firm’s price target on Ovid Therapeutics (OVID) to $5 from $3 and keeps a Buy rating on the shares. Phase 1 safety and tolerability results of OV329 7mg dose cohort “truly impressed us and are nicely aligned with that of prior dose cohorts,” says the analyst, who increased the firm’s view of the probability of approval for OV329 to 40% from 35%.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OVID:
- Ovid Therapeutics: Advancing OV329 Pipeline, De‑Risked Differentiation, and Strong Cash Runway Support Buy Rating
- Midday Fly By: General Mills reports downbeat Q3, Macy’s reports Q4 beat
- PolyPid Approaches NDA Submission as New Medicare Model Creates Strong Incentives for SSI Prevention
- Ovid Therapeutics Raises Capital to Expand Epilepsy Pipeline
- Ovid Therapeutics announces Phase 1 clearance for OV4071